You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

Details for Patent: 8,889,722


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,889,722 protect, and when does it expire?

Patent 8,889,722 protects MULPLETA and is included in one NDA.

This patent has twenty-six patent family members in twenty countries.

Summary for Patent: 8,889,722
Title:Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
Abstract: An optically active 4-phenylthiazole derivative having a thrombopoietin receptor agonist activity and a pharmaceutical composition containing the present compound as an active ingredient are created, and a platelet production regulating agent which can be orally administered is provided. Disclosed is a pharmaceutical composition containing, as an active ingredient, an optically active compound represented by the formula: ##STR00001## wherein, R.sup.1 is a halogen atom or C1-C3 alkyloxy; R.sup.2 is C1-C8 alkyl; R.sup.3 is C1-C8 alkyl; R.sup.4 and R.sup.5 are each independently a fluorine atom or chlorine atom; R.sup.6 is C1-C3 alkyl or C1-C3 alkyloxy; * indicates that a carbon atom marked with an asterisk is an asymmetric carbon, a pharmaceutically acceptable salt thereof, or a solvate thereof.
Inventor(s): Takayama; Masami (Osaka, JP), Kurose; Noriyuki (Osaka, JP)
Assignee: Shionogi & Co., Ltd. (Osaka-Shi, Osaka, JP)
Application Number:13/766,752
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,889,722

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vancocin Italia MULPLETA lusutrombopag TABLET;ORAL 210923-001 Jul 31, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,889,722

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2007-198590Jul 31, 2007

International Family Members for US Patent 8,889,722

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2184279 ⤷  Sign Up 300998 Netherlands ⤷  Sign Up
European Patent Office 2184279 ⤷  Sign Up 122019000065 Germany ⤷  Sign Up
European Patent Office 2184279 ⤷  Sign Up 2019C/534 Belgium ⤷  Sign Up
European Patent Office 2184279 ⤷  Sign Up CA 2019 00038 Denmark ⤷  Sign Up
European Patent Office 2184279 ⤷  Sign Up 132019000000090 Italy ⤷  Sign Up
European Patent Office 2184279 ⤷  Sign Up 1990035-6 Sweden ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.